2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Tumor Heterogeneity
Tumor heterogeneity, a hallmark of cancer, refers to the presence of diverse cell populations within a tumor. These cells vary in genetic, epigenetic, and phenotypic characteristics, leading to differences in proliferation rates, drug sensitivity, and metastatic potential. Understanding tumor heterogeneity is crucial for developing effective treatment strategies. Techniques like single-cell sequencing and spatial profiling have unveiled the intricate landscape of tumor heterogeneity, revealing subclones and microenvironments that influence disease progression and therapy response. Leveraging this knowledge, researchers aim to personalize cancer treatment by targeting specific tumor cell populations and their associated vulnerabilities. By unraveling the complexity of tumor heterogeneity, scientists strive to improve patient outcomes and pave the way for precision oncology.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China